Arcus Biosciences, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2022-06-30 was $2.30M, a 64.71% increase year-over-year.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2021-06-30 was $1.39M, a 129.65% increase year-over-year.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2020-06-30 was $607.00K, a 1.85% increase year-over-year.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2019-06-30 was $596.00K.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $3.02M, a 90.42% increase from fiscal 2020.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2020 was $1.59M, a 54.23% increase from fiscal 2019.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2019 was $1.03M, a 37.02% increase from fiscal 2018.
- Arcus Biosciences, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2018 was $751.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2022-06-30 | $2.30M 10-Q · filed 2022-11-02 | |
| 2021-12-31 | $3.02M 10-K · filed 2022-02-23 | |
| 2021-06-30 | $1.39M 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $1.59M 10-K · filed 2022-02-23 | |
| 2020-06-30 | $607.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $1.03M 10-K · filed 2022-02-23 | |
| 2019-06-30 | $596.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $751.00K 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |